Trial Profile
Prospective, single-centre study investigating efficacy of immunotherapy (Ipilimumab or Interleukin-2) after regional chemotherapy in patients with in-transit melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Interleukin-2 (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Dec 2015 New trial record